Rowinsky E K, Donehower R C, Jones R J, Tucker R W
Johns Hopkins Oncology Center, Baltimore, Maryland 21205.
Cancer Res. 1988 Jul 15;48(14):4093-100.
Taxol, a diterpenoid plant product that enhances the polymerization of tubulin, is currently entering clinical trials in the treatment of human leukemia. In order to develop an in vitro assay to predict tumor sensitivity to taxol, human leukemic cell lines were exposed to clinically achievable concentrations of taxol for relevant exposure periods. Changes in microtubules visualized by indirect immunofluorescence were compared to drug sensitivity measured by a clonogenic assay. Taxol produced either multiple mitotic asters in G2/M or microtubule bundling throughout the cell cycle. In cells that were relatively resistant to taxol, microtubule bundling was reversible while microtubule bundling in relatively sensitive cells persisted in the presence or absence of taxol. In contrast, aster formation was unrelated to cytotoxicity in any cell line. In the future, these microtubule effects may be useful in predicting the chemotherapeutic efficacy of taxol.
紫杉醇是一种能促进微管蛋白聚合的二萜类植物产物,目前正进入治疗人类白血病的临床试验阶段。为了开发一种体外检测方法来预测肿瘤对紫杉醇的敏感性,将人类白血病细胞系暴露于临床可达到的紫杉醇浓度下,并持续相关的暴露时间。通过间接免疫荧光观察到的微管变化与通过克隆形成试验测定的药物敏感性进行了比较。紫杉醇在G2/M期产生多个有丝分裂星状体,或在整个细胞周期中导致微管束化。在对紫杉醇相对耐药的细胞中,微管束化是可逆的,而在相对敏感的细胞中,无论有无紫杉醇,微管束化都会持续存在。相比之下,星状体的形成与任何细胞系的细胞毒性均无关。未来,这些微管效应可能有助于预测紫杉醇的化疗疗效。